Manistee Therapeutics is developing a novel sublingual therapy specifically designed for migraine treatment. The company is currently conducting a clinical trial to evaluate an investigational drug for stopping migraine headache symptoms in adults. This research aims to provide a new therapeutic option for individuals managing chronic migraine pain.
Funding
Funding not disclosed
Founders
Product
Problem
Migraine affects a significant portion of the global population, leading to severe impairment and reduced productivity, with limited therapy options suitable for all ages. Current treatments do not address the underlying causes related to genetic predisposition and environmental factors impacting the frequency of attacks. There is a need for more diverse and effective therapeutic interventions.
Solution
Manistee Therapeutics is developing a novel sublingual therapy aimed at relieving migraine symptoms in adults. The company's approach is rooted in dedicated scientific observations and study, with a focus on addressing both the genetic and environmental factors contributing to migraine. By engaging patients in clinical trials, Manistee Therapeutics seeks to provide a new treatment option that can improve the quality of life for individuals suffering from migraines. The company is currently enrolling participants in a clinical study to evaluate the investigational drug's efficacy in stopping migraine symptoms.
Target Audience
The primary target audience includes adults suffering from migraine headaches, as well as medical professionals and researchers in the field of neurology and pain management.
Features
- Novel sublingual drug formulation for migraine relief.
- Clinical trials focused on adult migraine sufferers.
- Investigational drug designed to stop the symptoms of a migraine headache.
- Future trials planned for preventive treatment of chronic migraine in adults.